Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial CO.28 Central Activation

CCTG-led trial NEOADJUVANT CHEMOTHERAPY, EXCISION AND OBSERVATION FOR EARLY RECTAL CANCER: The NEO Trial. CCTG Trial CO.28 has been centrally activated.


Eligibility:
  • Histologically confirmed invasive well-moderately differentiated rectal adenocarcinoma diagnosed within 90 days prior to enrollment
  • Tumour stage cT1-T3abN0 based on pelvic MRI
  • cN0 stage based on pelvic MRI
  • No contraindications to protocol chemotherapy
  • M0 stage based on no evidence of metastatic disease by CT imaging
  • Mid to low-lying tumor eligible for local tumor excision in the opinion of the treating surgeon
  • Medically fit to undergo radical surgery as per treating surgeon's discretion
  • Patient does not have pathologic high-risk factors on either/ or the initial biopsy specimen report or follow up biopsy (if done): high histologic grade, mucinous histology, lymphatic or vascular invasion

Objectives: Protocol specified organ preservation rate

If you have any questions please contact Study Coordinator Alexander Montenegro amontenegro@ctg.queensu.ca